Towards Healthcare Research & Consulting

Adapalene Companies, Latest Updates and Market Growth 2026-2035

Date : 31 March 2026

Top Adapalene Market Companies, Growth and Latest Updates 2026

Adapalene Market Companies are

Now it’s effortless to manage all your Market data with 30+ powerful features for your business in one powerful place: Access the Dashboard

Company Headquarters Latest Update
Perrigo Company plc Ireland Perrigo organization is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that improve patients' well-being by empowering consumers to proactively prevent or treat conditions that are self-managed.
Galderma S.A Switzerland Galderma continues to strengthen its leadership in acne treatment, focusing on its established selection.
Teva Pharmaceutical Industries Ltd Israel Teva Pharmaceutical Industries Ltd. continues to provide generic Adapalene 0.1% Gel as part of its expansive dermatology portfolio.
Glenmark Pharmaceuticals Ltd  United States In November 2025, Glenmark Pharmaceuticals, also with Dublin-based Cosmo Pharmaceuticals N.V., received conventional market authorisation (MA) from the European Commission (EC)for an acne management cream in 15 European countries.
Sun Pharmaceutical Industries Ltd India Sun Pharmaceutical Ind. Ltd. offers a broad range of active pharmaceutical ingredients, which includes adapalene. It belongs to the retinoid agent calming category.
Dr. Reddy’s Laboratories Ltd India This organization is actively increasing its dermatology and over-the-counter (OTC) portfolios.

Supply Chain Analysis

R&D:

  • Research and development (R&D) for adapalene involves advanced formulation technology, characterization, stability testing, and in vitro/in vivo effectiveness research.
  • Key Players: Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd.

Manufacturing Processes:

  • Manufacturing processes in adapalene involve the biochemical synthesis of the active pharmaceutical ingredient (API) and the pharmaceutical formulation into topical products such as gels or creams.
  • Key Players: Perrigo Company plc and Glenmark Pharmaceuticals Ltd.

Patient Services:

  • Patient services, including adapalene, primarily focus on the diagnosis, prescription, and long-term management of acne vulgaris and different dermatological conditions.
  • Key Players: Galderma S.A. and Teva Pharmaceutical Industries Ltd

Market Growth

The global adapalene market size was estimated at USD 611.1 million in 2025 and is predicted to increase from USD 635.18 million in 2026 to approximately USD 899.37 million by 2035, expanding at a CAGR of 3.94% from 2026 to 2035.

Adapalene Market Size is USD 635.18 Million in 2026.

Our experts provide regional insights, growth stats, competitor analysis and many more customized requirements to help you stay ahead: Download for FREE

Recent Developments in the Adapalene Market

  • In August 2025, Bausch Health, Canada Inc., part of Bausch Health Companies Inc., a worldwide, diversified pharmaceutical organization, announced that PrCABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to recipients of the public drug plans of Quebec and Saskatchewan
  • In September 2025,  Sol-Gel Technologies, Ltd., a dermatology organization, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 for Gorlin syndrome, a Phase-1b, double-blinded clinical trial of SGT-210 on Darier disease patients, and with two approved large-category dermatology products, TWYNEO and EPSOLAY, announced that Health Canada issued a Notice of Compliance (NOC) for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults.
  • In April 2025, Sol-Gel Technologies, Ltd., a clinical-stage dermatology organization, announced it had entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO.